Vizgen

Spatial multi-omics at subcellular resolution for biological research, AI-driven discovery and drug development

Vizgen® is at the forefront of spatial multi-omics, building technologies that measure genes and proteins in their spatial context at subcellular resolution and reveal how individual cells organize, interact and drive biological processes within tissue. Its MERSCOPE Ultra™ Platform, MERFISH 2.0™ chemistry and InSituPlex® protein assays are used in academic research and in biopharma discovery and development across therapeutic areas including oncology, neuroscience and immunology, from mapping cell types in the brain to validating drug targets in tumor tissue. Through Velocity Lab™, Vizgen also generates spatial datasets with partners at the scale required to train AI models of biology for drug discovery.

Vizgen was co-founded by leaders in single-cell and spatial genomics, including Xiaowei Zhuang, PhD, David Walt, PhD, and Jeffrey Moffitt, PhD. The company is headquartered in Waltham, Massachusetts, and backed by leading life science investors including ARCH Venture Partners, M Ventures, Northpond Ventures, Tao Capital Partners, Sofina and Blue Water Life Science Advisors.